Now showing items 1-4 of 4
Mergers, Acquisitions, and Alliances
(The Oxford Handbook of the Economics of the Biopharmaceutical Industry, 2012-09-18)
© 2012 by Oxford University Press. All rights reserved.This article considers the determinants and effects of M&As in the pharmaceutical industry, with a particular focus on innovation and R&D productivity. As is the case ...
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
(Health Aff (Millwood), 2011-11)
The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raises questions about whether the act's intended balance of incentives for cost savings and continued innovation has been achieved. ...
Generic competition and market exclusivity periods in pharmaceuticals
(Managerial and Decision Economics, 2007-06-01)
In this paper we examine generic competition and market exclusivity periods for pharmaceuticals experiencing their initial generic entry between 1995 and 2005. We find that generic competition has increased over several ...
Mergers and Alliances in Pharmaceutical: Effects on Innovation and R&D Productivity
(The Economics of Corporate Governance and Mergers, 2008-01-01)
This book provides an insightful view of major issues in the economics of corporate governance (CG) and mergers. It presents a systematic update on the developments in the two fields during the last decade, as well ...